Is an electronic signature legally valid?

Yes. Under the federal ESIGN Act (15 U.S.C. ch. 96) and most states’ UETA statutes, an electronic signature can have the same legal effect as a handwritten signature when intent, consent, attribution, and retention requirements are met.

Do consumer or healthcare forms need a consent notice?

Consumer-facing and certain healthcare records require an ESIGN consumer disclosure and affirmative consent to receive electronic records. Follow 15 U.S.C. §7001(c) procedures before relying solely on e-delivery.

Is notarization required for FDA submissions?

Most FDA initial filings do not require notarization, but specific documents may. Notarization and RON acceptance vary by state; verify requirements with the applicable state notary authority before obtaining notarization.

Can I use an eSignature vendor for PHI?

Yes with safeguards. Use a vendor that supports HIPAA and execute a Business Associate Agreement (BAA) before transmitting protected health information to meet HIPAA obligations.

How do I correct a submitted form?

If an error is discovered after submission, follow the FDA’s instructions for amendments or corrections for that submission type and preserve prior records; keep a clear audit trail of the change and its authorization.

What records should I retain and for how long?

Retain initial forms and related correspondence per applicable rules: IRS generally 3 years (IRC §6501(a)), HIPAA records 6 years (45 CFR §164.530(j)), and SEC or industry-specific rules where applicable; state requirements may be longer.

Electronic Signature
Templates
Healthcare
Healthcare FDA Initial Form

Healthcare FDA Initial Form

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Healthcare FDA Initial Form

This form collects initial demographic, clinical, and authorization information necessary to permit disclosure of protected health information to regulatory authorities and study sponsors in connection with FDA-regulated care or evaluation. Completion of this form enables treatment, regulatory reporting, safety monitoring, and, where applicable, participation in investigational programs. Signing this form grants the specific authorizations described below; it does not waive any legal rights except as explicitly stated.

Patient Information

Patient Name:

Date of Birth: Gender: Male Female Other/Prefer not to say

Address Primary Phone Email Emergency Contact (Name, Relation, Phone) Facility/Patient Identifiers (if applicable)

Insurance Information

Primary Insurance Provider Policy Number Group Number Subscriber Name

Medical History

Current Medications Allergies (including drug, food, latex) Prior Surgeries / Hospitalizations (dates and reason) Chronic Conditions / Diagnoses

Implanted medical device: Yes No If yes, specify device:

Pregnancy status (if applicable): Yes No Unknown

FDA-Regulated Procedure / Study Information

Brief description of proposed FDA-regulated intervention, investigational product, or protocol:

Risks and benefits: The patient has been advised that the proposed evaluation or intervention is subject to FDA oversight and may involve risks, including but not limited to adverse reactions, procedure-related complications, and unanticipated outcomes. Expected benefits, if any, and available alternatives have been discussed. Participation or receipt of the FDA-regulated product is voluntary and may be withdrawn at any time without forfeiting standard care.

Patient Acknowledgement

I acknowledge I have received and understand the risks, benefits, and alternatives of the proposed FDA-regulated procedure described above.

Consent to Receive or Participate (if applicable)

I consent to receive the FDA-regulated treatment or to participate in the described protocol, subject to the terms of this form and any separate consent document.

Authorization to Disclose Health Information to FDA and Related Parties

I hereby authorize the release of my medical records, test results, images, and other protected health information to: the Food and Drug Administration (FDA), the clinical study sponsor, Institutional Review Board (IRB), and other agents involved in regulatory review, safety monitoring, and required audits. This information may include diagnostic information, treatment records, and other information necessary for regulatory oversight, adverse event reporting, and aggregate safety analysis.

Specific authorized recipients (check all that apply):

FDA and its authorized representatives
Study sponsor or manufacturer
Institutional Review Board (IRB) or ethics committee
Other treating providers involved in my care

Purpose of disclosure: regulatory review, safety monitoring, adverse event reporting, audit, and potential research analysis necessary to evaluate safety and effectiveness of the product or procedure.

Expiration of authorization (select one and provide date if applicable):

This authorization expires on:

This authorization expires upon conclusion of the regulatory review related to this treatment/protocol.

Revocation: I understand I may revoke this authorization at any time by providing a written revocation to the facility's records office. Revocation will not affect disclosures already made in reliance on this authorization prior to receipt of the revocation. Information disclosed under this authorization may be subject to redisclosure by the recipient and may no longer be protected by federal privacy rules.

HIPAA Acknowledgement and Certifications

I acknowledge receipt of the facility's Notice of Privacy Practices and understand that my protected health information may be used or disclosed for treatment, payment, healthcare operations, and for the regulatory purposes described above. I certify that the medical and insurance information I have provided is true and complete to the best of my knowledge. I understand that falsification of information may affect eligibility for treatment or study participation.

By signing below I authorize the release of my records as specified, acknowledge understanding of risks/benefits, and consent to the disclosures described on this form where I have indicated consent. My consent is voluntary.

Additional Comments or Limitations on Disclosure

Signature

I certify that I am the patient or the patient's legal representative and that I am authorized to sign this document.

Patient / Representative Printed Name:

Signature:

Relationship to Patient (if signed on behalf of patient):

Date:

What the Healthcare FDA Initial Form Is and when it applies

The Healthcare FDA Initial Form is the standard document organizations complete to open an FDA-regulated interaction such as facility registration, product listing, or an initial premarket communication. It captures identifying details, contact information, and primary product or establishment descriptors so the agency can create a formal record and assign tracking identifiers. Completing the form accurately establishes a filing date, launches administrative intake procedures, and provides the baseline data reviewers use for follow-on submissions, labeling reviews, and inspection planning.

Why a correct initial form matters for regulatory progression

A complete Healthcare FDA Initial Form creates an auditable record, establishes procedural priority with the agency, and reduces follow-up requests. Accurate initial data lowers the risk of administrative rejection, shortens intake cycles, and helps ensure subsequent filings reference consistent identifiers and contacts throughout review.

Who typically prepares and signs the initial FDA filing

Organizations and individuals vary by use case, but several profiles commonly prepare this form.

Manufacturers and sponsors: Regulatory affairs teams submitting first-time product or establishment information to begin FDA processes.
Clinical sites and laboratories: Administrative staff or compliance officers registering facilities or reporting program participation as required.
Consultants and counsel: Regulatory consultants or attorneys preparing filings and verifying legal authority and completeness prior to submission.

Confirm the appropriate signer and supporting paperwork for your submission pathway and retain proofs of authority.

Stepwise workflow to complete and validate the initial form

Follow these core steps to prepare, review, and submit the Healthcare FDA Initial Form with supporting documentation.

01

Prepare: Gather IDs, product details, and required attachments.
02

Enter Data: Populate fields exactly and use MM/DD/YYYY for dates.
03

Review: Internal legal and regulatory review for authority and completeness.
04

Submit: Send via the chosen eSubmission channel and retain confirmation.

Typical routing and confirmation steps after submission

A standard routing sequence captures document state, signer actions, and agency acknowledgment while preserving an audit trail for inspection and tracking.

Upload: Place the completed form and attachments into the submission package.
Assign Signers: Designate who signs and their signing order, if applicable.
Authenticate: Use required signer authentication such as email or stronger methods.
Acknowledge: Receive confirmation and retain the agency-assigned identifier.

Recommended online workflow settings for regulatory filings

Configure an online workflow to reflect required authentication, signature type, and notification settings before distribution.

Field	Configuration
Authentication	Email link with optional SMS code recommended
Signature Type	Simple e-signature or PKI-based digital signature if required
Routing	Sequential or parallel signer order depending on authority
Notifications	Automated email reminders and final completion receipts

Technical considerations for electronic completion and submission

Select delivery and integration methods that meet privacy, authentication, and recordkeeping needs for regulatory submissions.

Formats: PDF, DOCX, and HTML supported
Integrations: Salesforce, NetSuite, Microsoft 365, Google Workspace
Authentication: Email link, SMS code, KBA, or SSO options

Security and compliance controls to look for

Encryption: TLS 1.2/1.3 in transit; AES-256 at rest

Certifications: SOC 2 Type II and ISO 27001 certified

HIPAA: Compliant when a BAA is executed

21 CFR Part 11: Capabilities to support compliant records and signatures

Audit Trail: Timestamps, IP addresses, and action history

Access Controls: SSO, role-based permissions, and MFA options

Primary risks and potential consequences of incorrect filings

Submission Rejection: Incomplete entries can cause rejection

Processing Delays: Missing items prolong agency review

Enforcement Action: False statements may trigger regulatory action

Clinical Impact: Delays may affect patient access

Increased Costs: Corrective filings and legal review add expense

Record Inconsistency: Mismatched identifiers cause audit complications

Common preparation errors that slow FDA intake

Using inconsistent product names or model numbers across filings creates mismatched records and often prompts administrative clarification requests from reviewers.
Failing to attach required technical documents, labeling, or device descriptions leads to deficiency letters and extended review cycles.
Submitting with signer names or titles that do not reflect corporate authority results in rejected filings or requests for validated signatory proof.
Entering dates or identification numbers in nonstandard formats causes processing errors and complicates audit trails during inspections.

Timing expectations and response windows for initial submissions

Timing varies by submission type; plan internal review, agency intake, and ample time for deficiency responses to avoid procedural withdrawals.

Initial Filing Date:

Establishes receipt and may affect procedural priority

Internal Review Window:

Allocate time for QA, legal, and regulatory checks

Agency Intake Period:

FDA performs administrative checks and assigns identifiers

Deficiency Response Deadline:

Respond promptly to prevent withdrawal or delay

Final Determination:

Timing depends on the chosen review pathway

eSignature vendor comparison for form completion and eSubmission

Baseline vendor pricing and feature availability relevant to completing and securely submitting the Healthcare FDA Initial Form; signNow is listed first for column ordering.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies by promotion	Varies by promotion	Varies by plan	Varies by plan
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No
Envelope Cap	No cap	100 envelopes/user/year	Varies by plan	Varies by plan	Varies by plan

Frequently asked questions about completing and eSigning the initial form

Answers to common questions about legal validity, signatures, notarization, vendor compliance, and recordkeeping for the Healthcare FDA Initial Form.

Need help? Contact support

Is an electronic signature legally valid?
Yes. Under the federal ESIGN Act (15 U.S.C. ch. 96) and most states’ UETA statutes, an electronic signature can have the same legal effect as a handwritten signature when intent, consent, attribution, and retention requirements are met.
Do consumer or healthcare forms need a consent notice?
Consumer-facing and certain healthcare records require an ESIGN consumer disclosure and affirmative consent to receive electronic records. Follow 15 U.S.C. §7001(c) procedures before relying solely on e-delivery.
Is notarization required for FDA submissions?
Most FDA initial filings do not require notarization, but specific documents may. Notarization and RON acceptance vary by state; verify requirements with the applicable state notary authority before obtaining notarization.
Can I use an eSignature vendor for PHI?
Yes with safeguards. Use a vendor that supports HIPAA and execute a Business Associate Agreement (BAA) before transmitting protected health information to meet HIPAA obligations.
How do I correct a submitted form?
If an error is discovered after submission, follow the FDA’s instructions for amendments or corrections for that submission type and preserve prior records; keep a clear audit trail of the change and its authorization.
What records should I retain and for how long?
Retain initial forms and related correspondence per applicable rules: IRS generally 3 years (IRC §6501(a)), HIPAA records 6 years (45 CFR §164.530(j)), and SEC or industry-specific rules where applicable; state requirements may be longer.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now